Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Net Cash Flow (2016 - 2025)

ImmunityBio (IBRX) has disclosed Net Cash Flow for 12 consecutive years, with $28.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 10.92% to $28.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$54.5 million, a 55.31% increase, with the full-year FY2025 number at -$54.5 million, up 55.31% from a year prior.
  • Net Cash Flow was $28.2 million for Q4 2025 at ImmunityBio, up from -$76.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $134.5 million in Q3 2023 to a low of -$144.5 million in Q1 2022.
  • A 5-year average of $2.7 million and a median of $5.1 million in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 1564.0% in 2022, then surged 27334.8% in 2023.
  • ImmunityBio's Net Cash Flow stood at $116.5 million in 2021, then tumbled by 99.73% to $319000.0 in 2022, then soared by 27334.8% to $87.5 million in 2023, then tumbled by 63.87% to $31.6 million in 2024, then dropped by 10.92% to $28.2 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Net Cash Flow are $28.2 million (Q4 2025), -$76.8 million (Q3 2025), and $76.9 million (Q2 2025).